Skip to main content
58°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Rezolute, Inc.
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 06, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 14, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute to Participate in Upcoming Investor Conferences in September
September 06, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 27, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 23, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 08, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 10, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 15, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
November 09, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute to Present at the Jefferies London Healthcare Conference
November 01, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
October 20, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Tickers
RZLT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.